Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study

Clinical Genitourinary Cancer · Available online 17 Aug 2026 · In press · Journal article · DOI 10.1016/j.clgc.2026.102652

Authors (8)

Melanie Mayer, Nicholas J. Seewald, Ernesto Ulloa-Pérez, Blanca Homet Moreno, Chethan Ramamurthy, Aram Babcock, Haojie Li, Ronac Mamtani

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Volume

24

Issue

8

Pages

102652

Year

2026

Citation

Mayer, M., Seewald, N., Ulloa-Pérez, E., et al. (2026). Real-World Treatment Duration With First-line Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Cancer: A National Electronic Health Record Study. Clinical Genitourinary Cancer. https://doi.org/10.1016/j.clgc.2026.102652

Related articles

• Utility of Circulating Tumor DNA as a Monitoring Tool for Marker-Negative Germ Cell Tumors and Somatic Type Malignancies · Clinical Genitourinary Cancer · 2026 · Same journal
• The Utility of the Comprehensive Complication Index in Demonstrating the Complication Burden and Predicting Length of Stay in Robot-Assisted Radical Prostatectomy · Clinical Genitourinary Cancer · 2026 · Same journal
• Real-World Effectiveness and Tolerability of Belzutifan in Sporadic Clear Cell Renal Cell Carcinoma: A Retrospective Cohort Study With Exploratory Genomic Correlation · Clinical Genitourinary Cancer · 2026 · Same journal
• Exploration of the Challenges in the Management of Prostate Cancer in East Africa · Clinical Genitourinary Cancer · 2025 · Same journal
• Immunophenotyping and Molecular Patterns of Prostate Cancer in East Africa: Diagnostic and Prognostic Implications—A Systematic Review · Clinical Genitourinary Cancer · 2026 · Same journal
• Impact of Age on Outcomes in Metastatic Non–Clear Cell Renal Cell Carcinoma: A Real-World TriNetX Analysis From the Global Society of Rare Genitourinary Tumors (GSRGT) · Clinical Genitourinary Cancer · 2026 · Same journal
• Efficacy and Safety of Every Other Week Gemcitabine and Docetaxel (GEMDOC) in Heavily Pretreated Metastatic Castration Resistant Prostate Cancer: A Retrospective Real-world Analysis · Clinical Genitourinary Cancer · 2026 · Same journal
• A Real-World Prospective Study of Comprehensive Genomic Testing in Patients With Metastatic Castration-Resistant Prostate Cancer · Clinical Genitourinary Cancer · 2025 · Same journal
• Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules · Clinical Genitourinary Cancer · 2025 · Same journal
• Why Has Prostate Cancer Research Lagged Behind? Advocacy, Biology, and the Road Ahead · Clinical Genitourinary Cancer · 2026 · Same journal